Hindustan Bio Sciences Limited has submitted its quarterly regulatory certificate to BSE Limited, confirming compliance with SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The filing demonstrates the company's adherence to mandatory quarterly reporting requirements under securities market regulations.

Quarterly Dematerialization Report

The company reported no dematerialization activity during the fourth quarter of FY26. According to the certificate filed under Regulation 74(5), no equity shares were received for dematerialization during the entire quarter.

Regulatory Compliance Framework

The certificate was prepared based on confirmation received from M/s. Venture Capital and Corporate Investments Pvt. Ltd., which serves as the company's Registrar and Share Transfer Agent. This third-party verification ensures accuracy and compliance with SEBI's regulatory framework for depositories and participants.

The Registrar and Share Transfer Agent independently confirmed in their certificate dated April 6, 2026, that no securities were received for dematerialization or rematerialization during the quarter. This dual-layer verification process strengthens the reliability of the reported information.

Corporate Governance

The certificate was signed by Venkata Rama Mohan Raju Jampana, Managing Director of Hindustan Bio Sciences Limited, bearing DIN: 00060800. The document was digitally signed on April 14, 2026, reflecting the company's adoption of digital processes for regulatory compliance.

Market Context

The absence of dematerialization activity during Q4 FY26 indicates stable shareholding patterns without significant physical-to-electronic share conversions. This quarterly nil report fulfills the company's obligation to maintain transparency with stock exchanges and depositories regarding share transfer activities.

The filing to BSE Limited's Department of Corporate Services ensures that all stakeholders, including investors and regulatory authorities, have access to current information about the company's dematerialization status as required under securities market regulations.

Hindustan Bio Sciences Limited has successfully completed the newspaper publication of its unaudited financial results for Q3FY26, demonstrating compliance with regulatory requirements following its strong quarterly performance. The Hyderabad-based pharmaceutical company reported a profit of ₹8.20 lakhs for the quarter ended December 31, 2025, marking a significant turnaround from previous quarters.

Regulatory Compliance and Publication

The company has fulfilled its obligation under Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing its Q3FY26 unaudited financial results in newspapers. Managing Director Venkata Rama Mohan Raju Jampana (DIN: 00060800) confirmed the publication details in a formal intimation to BSE Limited on February 2, 2026.

Financial Performance Highlights

The company's Q3FY26 performance demonstrates remarkable improvement with total income reaching ₹40.03 lakhs, comprising revenue from operations of ₹1.78 lakhs and other income of ₹38.25 lakhs. This represents a substantial increase from the previous quarter where total income was only ₹0.86 lakhs.

Nine-Month Performance Overview

For the nine-month period ended December 31, 2025, Hindustan Bio Sciences reported positive results with a profit of ₹3.74 lakhs compared to a loss of ₹0.98 lakhs in the corresponding period of the previous year. Total income for the nine-month period reached ₹74.39 lakhs against ₹42.20 lakhs in the previous year, representing a growth of 76.30%.

Board Meeting and Compliance

The Board Meeting was held on January 31, 2026, at 2:00 PM at the company's registered office located at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad. The meeting concluded at 3:30 PM, during which directors approved the unaudited financial results along with the Limited Review Report. The results were subject to limited review by VASG & Associates, Chartered Accountants (FRN: 006070S).

Company Information

Hindustan Bio Sciences Limited operates from its registered office at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034. The company maintains its corporate identity number as L26942TG1991PLC013564 and can be contacted at +91 40 23555161/23555181. The paid-up equity capital remains constant at ₹205.02 lakhs with a face value of ₹2.00 per share.

Source: Company Filing